Measurement of patient compliance with drug therapy: An overview

Assessment in Behavioral Medicine

Volumn , Issue , 2013, Pages 215-243

  de Klerk, Erik ^a  

^a AARDEX   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85136047259     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Bandura, A. (1977) Analysis of self-efficacy theory of behavioral change. Cognitive Therapy Research, 1, 287-310.
2. CDP Group (1973). The Coronary Drug Project: Design, methods, and baseline results. Circulation, 47 (Suppl 1), 1-179.
3. CDP Group (1974). Clofibrate and niacin in coronary heart disease. Journal of Chronic Diseases, 27, 267-285.
4. CDP (1980). Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. New England Journal of Medicine, 303, 1038-1041.
5. Cox, D.R. (1998). Analyzing non-compliance in clinical trials. Invited discussion. Statistics in Medicine, 387-389.
6. Cramer, J.A., Mattson, R.H., Prevey, M.L., Scheyer, R.D., & Ouellette, V.L. (1989). How often is medication taken as prescribed? A novel assessment technique. Journal of American Medial Association, 261, 3273-3277.
7. Cramer, J., Vachon, L., Desforges, C., & Sussman, N.M. (1995). Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia, 36, 1111-1117.
8. de Geest, S. (1996). Subclinical non-compliance with immunosuppresive therapy in heart transplant recipients: A cluster analytic study. Doctoral thesis, Katholieke Universiteit Leuven, Leuven, Belgium.
9. de Geest, S. (1997). Personal communication with Dr. S. de Geest, Department of Public Health, University of Leuven, Belgium.
10. de Geest, S., Abraham, I., Gemoets, H., & Evers, G. (1994). Development of the long-term medication behaviour self-efficacy scale: Qualitative study for item development. Journal of Advanced Nursing, 19, 233-238.
11. de Klerk, E. (1997). Patient compliance in hypertension. CardioTopics, 4, 7-21.
12. de Klerk, E., & van der Linden, S.J. (1996). Compliance monitoring of NSAID drug therapy in ankylosing spondylitis: Experiences with an electronic monitoring device. British Journal of Rheumatology, 35, 60-65.
13. de Klerk, E., van der Heijde, D., & van der Linden, S. (1997a). Development of a measure for exploring variable patient compliance. Arthritis and Rheumatism, 40, S114.
14. de Klerk, E., van der Heijde, D., van der Linden, S., & Urquhart, J. (1997b). A simple yet effective patient compliance simulation model. Paper presented at the Modelling and Simulation of Clinical Trials and Drug Development Congress, Washington DC, USA.
15. de Klerk, E., van der Heijde, D., van der Tempel, H., & van der Linden, S. (1999). Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. Journal of Rheumatology, 26, 2635-2641.
16. Dolan-Mullen, P. (1997). Compliance becomes concordance. British Medical Journal, 314, 691-692.
17. Efron, B., & Feldman, D. (1991). Compliance as an explanatory variable in clinical trials. Journal of the American Statistical Association, 86, 9-26.
18. Feely, M., Cooke, J., Price, D., Singleton, S., Mehta, A., Bradford, L., & Calvert, R. (1987). Low-dose phenobarbitone as an indicator of compliance with drug therapy. British Journal of Clinical Pharmacology, 24, 77-83.
19. Feely, M., Price, D., Bodansky, H.J., & Tindall, H. (1989). Use of a pharmacologic indicator to assess compliance with drug therapy in patients with poorly-controlled type II diabetes. British Journal of Clinical Pharmacology, 27, 101P-102P.
20. Feinstein, A.R. (1990). On white-coat effects and the electronic monitoring of compliance. Archives of Internal Medicine, 150, 1377-1378.
21. Feinstein, A.R. (1991). Intent-to-treat policy for analyzing randomized trials. Statistical distortions and neglected clinical challenges. In: J.A. Cramer & B. Spilker (Eds.), Patient compliance in medical practice and clinical trials (pp. 359-370). New York: Raven Press Ltd.
22. Girard, P., Sheiner, L.B., Kastrissios, H., & Blaschke, T.F. (1996). Do we need full compliance data for population pharmacokinetic analysis? Journal of Pharmacokinetics and Biopharmaceutics, 24, 265-281.
23. Goetghebeur, E.J., & Shapiro, S.H. (1996). Analysing non-compliance in clinical trials: Ethical imperative or mission impossible? Statistics in Medicine, 15, 2813-2826.
24. Guillebaud, J. (1993). Any questions? British Medical Journal, 307, 617.
25. Harter, J.G., & Peck, C.C. (1991). Chronobiology. Suggestions for integrating it into drug development. Annals of the New York Academy of Science, 618, 563-571
26. Hasford, J. (1991). Biometric issues in measuring and analyzing partial compliance in clinical trials. In: J.A. Cramer & B. Spilker (Eds.), Patient compliance in medical practice and clinical trials (pp. 265-281). New York: Raven Press Ltd. Hippocrates. (ca 400 BC). Decorum.
27. Joyce, C.R.B. (1962). Patient cooperation and the sensitivity of clinical trials. Journal of Chronic Diseases, 15, 1025-1036.
28. Kass, M.A., Gordon, M., Morley, R.E., Jr., Meltzer, D.W., & Goldberg, J.J. (1987). Compliance with topical timolol treatment. American Journal of Ophthalmology 103, 188-193.
29. Lasagna, L., & Hutt, P.B. (1991). Health care, research and regulatory impact of non-compliance. In: J.A. Cramer & B. Spilker (Eds.), Patient compliance in medical practice and clinical trials (pp. 393-403). New York: Raven Press Ltd.
30. LRCPPT (1984a). The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association, 251, 351-364.
31. LRCPPT (1984b). The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Journal of the American Medical Association, 251, 365-374.
32. McGavock, H. (1996). A review of the literature on drug adherence. Queen's University, Belfast.
33. Moulding, T. (1962). Proposal for a time recording pill dispenser as a method for studying and supervising the self-administration of drugs. American Review of Respiratory Disorders, 85, 754-757.
34. Mushlin, A.I., & Appel, F.A. (1977). Diagnosing potential non-compliance. Physicians' ability in a behavioral dimension of medical care. Archives of Internal Medicine, 137, 318-321.
35. Peaker, S., Mehta, A.C., Kumar, S., & Feely, M. (1989). Measurement of low (sub-therapeutic) phenobarbitone levels in plasma by high-performance liquid chromatography: Application to patient compliance studies. Journal of Chromatography, 497, 308-312.
36. Pullar, T., Birtwell, A.J., Wiles, P.G., Hay, A., & Feely, M.P. (1988a). Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clinical Pharmacology and Therapeutics, 44, 540-545.
37. Pullar, T., Kumar, S., Tindall, H., & Feely, M. (1989). Time to stop counting the tablets? Clinical Pharmacology and Therapeutics, 46, 163-168.
38. Pullar, T., Peaker, S., Martin, M.F., Bird, H.A., & Feely, M.P. (1988b). The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. British Journal of Rheumatology, 27, 381-384.
39. Rubin, D.B. (1998). More powerful randomization-based p-values in doubleblind trials with non-compliance. Statistics in Medicine, 17, 251-267.
40. Sackett, D.L., & Haynes, R.B. (1976). Compliance with therapeutic regimens. Baltimore, MD: Johns Hopkins University Press.
41. Svarstad, B.L. Chewning, B.A., Sleath, B.L. & Claesson, C. (1999), The brief medication questionnaire: A tool for screening patient adherence and barriers to adherence. Patient Education & Counselling, 37, 113-124.
42. Urquhart, J. (1997). The electronic medication event monitor - lessons for pharmacotherapy. Clinical Pharmacokinetics, 32, 345-356.
43. Urquhart, J., & Chevalley, C. (1988). Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Information Journal, 22, 363-378.
44. van Wanghe, P., & Dequeker, J. (1982). Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases. Annals of Rheumatic Disorders, 41(Suppl 1), 40-43.
45. Vanhove, G.F., Schapiro, J.M., Winters, M.A., Merigan, T.C., & Blaschke, T.F. (1996). Patient compliance and drug failure in protease inhibitor monotherapy. Journal of the American Medical Association, 276, 1955-1956.
46. Vrijens, B., & Goetghebeur, E. (1997). Comparing compliance patterns between randomized treatments. Controlled Clinical Trials, 18, 187-203.
47. Waterhouse, D.M., Calzone, K.A., Mele, C., & Brenner, D.E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology, 11, 1189-1197.
48. Weis, S.E., Slocum, P.C., Blais, F.X., King, B., Nunn, M., Matney, G.B., Gomez, E., & Foresman, B.H. (1994). The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. New England Journal of Medicine, 330, 1179-1184.